At the onset of the Covid-19 outbreak, misinformation spread rapidly via mainstream and social media that left many questioning the safety of ibuprofen to manage Covid-19 symptoms. At the time, there was no medical consensus that could dispel the rumors circulating about ibuprofen; and as a result, there was an information gap growing about ibuprofen. GlaxoSmithKline (GSK), the makers of Advil, engaged Edelman to quickly address the issue and develop a plan to correct the misinformation and protect the brand from future risk.